LATAM MedTech Insights

In this episode of LATAM MedTech Insights, we break down the critical new IVD regulation in Brazil, RDC 830/2023. This isn't just another update; it's a complete overhaul that aligns In-Vitro Diagnostic devices with the stringent framework of the general medical device regulation, RDC 751/2022, creating a new set of rules and unexpected hurdles for manufacturers. We uncover the hidden complexities within this harmonization effort, from reclassifying your product's risk level to meeting demands for more robust clinical evidence and local performance data. This shift signals ANVISA's move towards a more demanding and localized regulatory system, making prior foreign approvals less of a guarantee for market access. A specific case involves a European diagnostics firm whose Class C diabetes monitoring IVD, previously accepted with its existing technical file, now faces rejection. The reason is a buried requirement in the new framework demanding stability studies validated against Brazil’s specific climate zones, a detail that could delay their launch by nine months and require a costly new data generation process. Key Takeaways: * How does RDC 830/2023 officially change the risk classification for your IVD device? * What are the three new documentation requirements inherited from RDC 751 that most IVD manufacturers are missing? * Why might your existing EU or FDA clinical data be insufficient for ANVISA now? * What is the single most common reason for submission delays under this new regulation? * How can your choice of a Brazilian Registration Holder (BRH) make or break your new application? * Are your current labels and instructions for use compliant with the new, stricter requirements? * What post-market surveillance activities are now mandatory for your IVD device in Brazil? Don't let regulatory surprises derail your expansion into Latin America. Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI tools to streamline global market access for MedTech and IVD companies. We act as your local representative, manage technical dossiers, and provide continuous regulatory monitoring to keep you ahead of changes like RDC 830. To secure your market presence in Brazil, contact us at [email protected] or visit https://pureglobal.com/.

Brazil just added a complex new layer to its AI MedTech regulations. Last week, the Federal Council of Medicine (CFM) issued Resolution 2,454, a framework that directly impacts how physicians can use AI tools. This isn't about device registration through ANVISA; it's about winning the trust and acceptance of the end-users—the doctors themselves. This episode dives deep into what this resolution means for foreign MedTech innovators. We explore how this new ethical and governance-focused oversight creates a dual-approval landscape where both regulatory bodies and medical associations hold the keys to market access. We break down the unwritten rules and hidden challenges that your company will now face in Latin America's largest market. Imagine your AI-powered diagnostic software, already successful in Europe, is being trialed in a major São Paulo hospital. Suddenly, the clinical lead halts the trial. The reason? Your firm can't produce a satisfactory governance report detailing how the AI's algorithms align with the CFM's new ethical guidelines, creating a market-access roadblock that no one saw coming. In this episode, you will learn: - What are the crucial differences between ANVISA's requirements and the CFM's new AI resolution? - Why might your international clinical data be insufficient to gain physician trust in Brazil? - How does a doctor's new "right of refusal" for AI tools change your market entry strategy? - Is this new resolution a hidden barrier or an opportunity to build a stronger competitive moat? - What kind of local data and governance documentation do you now need to prepare? - How can you proactively engage with Brazil's medical community to ensure adoption? - What are the three key steps to de-risk your AI MedTech launch in this new environment? Struggling to keep up with shifting regulations in LATAM? At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies, leveraging local expertise and advanced AI tools to streamline your market access. From acting as your local representative in Brazil to compiling technical dossiers with our AI platform, we turn regulatory hurdles into market opportunities. Don't let compliance challenges slow your growth. Contact us at [email protected] or visit https://pureglobal.com/ to secure your foothold in Latin America.

This week on LATAM MedTech Insights, we dissect the breaking news from Brazil. ANVISA has unexpectedly tightened its cybersecurity regulations for Software as a Medical Device (SaMD), creating significant new challenges for foreign manufacturers. We explore the specific documentation now required and what this means for anyone trying to enter Latin America's largest market. This move signals a major shift in the region's regulatory philosophy, moving away from simple adoption of global standards towards hyper-local requirements tied to national laws like the LGPD. We analyze the immediate impact on companies with pending applications, using a real-world example of a European company whose market entry is now stalled, facing unforeseen costs and significant delays. Key Questions Answered: - What specific cybersecurity evidence does ANVISA now demand beyond FDA or CE Mark documentation? - How does Brazil's data privacy law (LGPD) create unique compliance risks for MedTech manufacturers? - Why is a global cybersecurity plan now insufficient for a successful Brazilian market submission? - What are the most common pitfalls leading to deficiency letters from ANVISA for SaMD products? - Are other LATAM countries like Mexico and Colombia expected to follow Brazil's lead? - How can you turn this complex new regulatory hurdle into a competitive advantage? - What should be included in a post-market surveillance plan to satisfy these new requirements? Navigating sudden regulatory shifts is what we do best. Pure Global offers end-to-end regulatory consulting, leveraging local expertise and advanced AI tools to streamline your market access. Whether it's developing a new regulatory strategy, compiling technical dossiers, or acting as your local representative, we ensure you stay ahead of the curve. Don't let regulatory surprises derail your LATAM expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

This week, we dissect a game-changing announcement from Brazil's ANVISA: a new "fast-track" approval process for AI-powered medical devices. While it promises rapid market access, it hides significant challenges beneath the surface that could derail unprepared international companies. This episode explores how Brazil's stringent data privacy law, the LGPD, is interwoven into this new regulatory pathway. We reveal why your existing global compliance frameworks might be insufficient and what specific steps are necessary to successfully navigate this complex but promising opportunity in Latin America's largest MedTech market. **Case Study:** Learn from the missteps of a European AI-diagnostic firm that saw its "fast-track" submission in Brazil stall due to unforeseen data validation requirements and non-compliance with local data privacy nuances, turning a promising opportunity into a costly delay. **This week's key questions:** - What specific device classes are eligible for ANVISA's new AI fast-track? - How does Brazil's LGPD law create unique compliance traps for foreign MedTech firms? - Why might your existing clinical data be rejected by Brazilian regulators? - What are the three biggest mistakes companies make when entering this new pathway? - Is the fast-track a genuine opportunity or a resource drain for non-specialists? - How can a local regulatory partner de-risk your entire market entry strategy? Pure Global offers end-to-end regulatory consulting solutions for Medical Technology (MedTech) and In-Vitro Diagnostic (IVD) companies, combining local expertise with advanced AI and data tools to streamline global market access. Contact Pure Global at [email protected] or visit us at https://pureglobal.com/.

Last week, Brazil's regulatory agency, ANVISA, issued an unexpected technical guidance that reclassifies certain Software as a Medical Device (SaMD) products. This move has sent shockwaves through the digital health sector, pushing many devices that rely on predictive algorithms into higher-risk categories overnight, invalidating existing registrations. In this episode of LATAM MedTech Insights, we break down what this clarification means for manufacturers, the new clinical evidence required for compliance under RDC 751, and why this signals a major strategic shift in Brazil's approach to digital health regulation. We explore the immediate commercial impact and the long-term strategic adjustments companies must now consider. Case in Point: Imagine your popular diabetes management app was approved as a Class II device. Suddenly, ANVISA's new interpretation of its predictive algorithm makes it a Class III product. Your registration is now invalid, marketing must cease, and you face the monumental task of generating local clinical data for a completely new submission. This is the exact challenge facing companies in Brazil right now. This episode's key questions: - How can a simple "technical guidance" invalidate your existing product registration in Brazil? - What specific software functions are now considered high-risk by ANVISA? - Is your current technical dossier prepared for this new level of scrutiny? - Why is relying on your existing EU or FDA clearance no longer enough for the Brazilian market? - What are the immediate steps you must take if your SaMD product is affected? - How does this change impact the market entry strategy for new digital health products in LATAM? - Could this regulatory pattern be replicated in other key LATAM markets? Feeling overwhelmed by the shifting regulatory landscape? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise in over 30 markets, including Brazil, with advanced AI tools to streamline global market access and ensure you stay compliant. Don't let regulatory surprises derail your strategy. Contact us for a consultation at [email protected] or visit https://pureglobal.com/.

This week on LATAM MedTech Insights, we dive into the significant new regulatory guidance from Brazil's ANVISA that is reshaping the landscape for Software as a Medical Device (SaMD). This update brings Brazil closer to global standards but introduces critical new challenges for foreign manufacturers in areas like risk classification, AI validation, and cybersecurity. We explore the immediate impact on MedTech companies aiming for the Brazilian market. For example, a US-based digital health firm was on the verge of submitting its product for approval. Now, they're confronting the painful reality that their AI algorithm's validation data is insufficient under the new, stricter guidelines, forcing them into a costly and time-consuming redevelopment cycle just to meet compliance. This episode unpacks how to anticipate and navigate these exact scenarios. Key Takeaways: - What are the three most critical changes in ANVISA's new SaMD framework? - How will the new risk classifications impact your product's path to market? - Are your cybersecurity measures compliant with both ANVISA's new rules and Brazil's LGPD? - What new clinical evidence is required for AI and machine learning-driven SaMD? - How can you leverage your existing international dossiers for the new submission process? - Why might your previous go-to-market strategy for Brazil now be obsolete? - What is the single biggest mistake companies make when interpreting new ANVISA guidance? Navigating evolving regulatory landscapes is our expertise. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local experts and advanced AI tools to streamline market access in over 30 countries, including Brazil. From regulatory strategy and dossier submission to acting as your local in-country representative, we turn complexity into clarity. Don't let regulatory hurdles derail your expansion. Contact us at [email protected] or visit https://pureglobal.com to learn more.

This week, we dive into a major regulatory shift in Brazil that just went live on March 1st, 2026. ANVISA's new Normative Instruction N°426/2026 activates the national UDI (Unique Device Identification) database, requiring manufacturers to submit detailed product data before entering the market. This episode breaks down the new requirements, the critical phased deadlines for different device classes, and the strategic implications for MedTech companies aiming to succeed in Latin America's largest market. We explore the hidden complexities, such as the absolute need for data equivalence between your ANVISA registration and your UDI submission. Consider the case of a cardiac stent manufacturer whose multi-million dollar product launch is completely stalled because of a single data mismatch in the new system. This highlights how a small administrative detail can become a major commercial barrier. Key Questions for This Episode: - Brazil's new UDI system just went live; are you prepared for the aggressive, risk-based deadlines? - What are the most common data mismatches that can block your market access? - Should you manage complex UDI submissions in-house or delegate them to a local Brazilian partner? - How does ANVISA's new database compare to the UDI systems in the US and Europe? - What is the single most critical step to take before submitting your first UDI record to ANVISA? - Are your current data management systems robust enough for this new era of traceability? - How can you leverage your Brazil Registration Holder to streamline this new compliance burden? At Pure Global, we specialize in turning these regulatory challenges into market opportunities. With our deep local expertise in Brazil and advanced AI-driven data tools, we provide end-to-end regulatory consulting to ensure your market access is seamless and compliant. We act as your local representative, manage technical dossier submissions, and navigate complex requirements like the new UDI system. To streamline your entry into Brazil and over 30 other global markets, contact us at [email protected] or visit https://pureglobal.com/.

This episode of LATAM MedTech Insights, brought to you by Pure Global, dives into the landmark regulatory shift just implemented by Brazil's ANVISA. We unpack the new RDC 830/2023 resolution for In-Vitro Diagnostic (IVD) devices, a critical update that redefines market access and compliance in Latin America's largest market. We explore how this harmonization with global standards impacts everything from risk classification to technical documentation. More importantly, we reveal the new strategic 'reliance pathway' that could dramatically accelerate your product's journey to market. Imagine your high-risk diagnostic device, facing a potential year-long review, suddenly becoming eligible for an expedited process in just a few months. This is now a reality for companies with existing approvals from major global authorities, but only if you know how to navigate the new system. Key questions answered in this episode: - What are the specific changes in ANVISA's new RDC 830/2023 for IVDs? - How do I determine if my IVD product's risk class has changed in Brazil? - What is the new 'reliance pathway' and which country approvals make me eligible? - How can leveraging my FDA or Health Canada approval cut my Brazilian registration time by over 70%? - What are the immediate steps my company must take to ensure compliance and avoid market access delays? - Does this change make Brazil a more attractive or more difficult market for IVD manufacturers? At Pure Global, we specialize in turning these complex regulatory updates into clear, actionable strategies. With local experts in Brazil and advanced AI tools, we manage the entire registration lifecycle, helping you leverage new pathways to gain a competitive edge. To ensure your company is prepared for the new era of IVD regulation in Brazil, contact us at [email protected] or visit https://pureglobal.com/.

A seismic regulatory shift is underway in Brazil, Latin America's biggest MedTech market. ANVISA's new Unique Device Identification (UDI) system, detailed in Normative Instruction 426/2026, is now being implemented. This isn't just a new labeling rule; it's a complex data management and submission challenge that could become a major barrier to market entry for unprepared device manufacturers. This episode breaks down exactly what the new requirements mean for your business. We go beyond the surface-level announcements to explore the practical, operational hurdles you will face. We discuss the critical importance of the SIUD database, the staggered compliance deadlines for different device classes, and why your existing global UDI strategy might not be enough for Brazil. Consider this: A successful European device company planned a major launch in Brazil, only to be halted for six months. The reason was not their product's quality, but their inability to provide the specific data attributes required by the new SIUD database, a detail they completely overlooked. This episode is designed to help you avoid that costly mistake. Key Takeaways: * What is Brazil's Normative Instruction 426/2026, and why is it a game-changer for market access? * How does the new SIUD database fundamentally alter device traceability requirements? * Are your data management systems prepared for the specific submission formats ANVISA demands? * What are the staggered compliance deadlines, and which one applies to your device portfolio? * Why is simply having a UDI on your label completely insufficient for the Brazilian market? * How can this regulatory hurdle be turned into a competitive advantage against slower rivals? * What are the most common pitfalls foreign manufacturers face when dealing with ANVISA's new rules? At Pure Global, we specialize in navigating these complexities. We provide end-to-end regulatory consulting, acting as your local representative and using advanced AI tools to ensure your technical dossiers are compliant and submitted efficiently. Don't let regulatory hurdles derail your expansion. Contact us at [email protected] or visit https://pureglobal.com/.

Brazil's MedTech market just experienced a seismic shift. ANVISA, the national regulatory agency, has rolled out its new comprehensive framework, RDC 751, fundamentally changing the rules for medical device registration and market access. This move aligns Brazil closer than ever with international standards like the EU MDR. In this episode, we break down what this massive overhaul means for manufacturers. We dissect the new risk classification system, the updated submission pathways, and the critical changes to technical dossier requirements, providing a clear roadmap for anyone looking to enter or stay in Latin America's largest healthcare market. Imagine a MedTech scale-up from the United States with an innovative orthopedic implant. They viewed Brazil as a primary expansion target but were stuck. Their main pain point was the regulatory divergence. Their FDA and EU technical files required a complete, costly, and time-consuming overhaul for the old Brazilian system, creating a barrier of over 18 months of work before they could even submit. With the new RDC 751, the question now is: can their existing EU MDR dossier fast-track their entry, or are there hidden complexities in the new rules that could still derail their launch? Key Takeaways: * How do the new four risk classes under RDC 751 compare to the previous Brazilian system? * What specific documents from my EU MDR technical file can be repurposed for a Brazilian submission? * Is the simplified `notificação` pathway truly faster for Class I and II devices? * What are the new labeling and IFU requirements that manufacturers often overlook? * How has the definition of a "medical device family" changed for submissions? * What are the new obligations for the Brazil Registration Holder (BRH) under RDC 751? * Are there any new post-market surveillance requirements that come with this framework? At Pure Global, we specialize in demystifying complex regulatory changes like Brazil's RDC 751. We offer end-to-end solutions, from developing a tailored regulatory strategy to compiling your technical dossier and acting as your local Brazil Registration Holder. Our unique blend of local expertise and advanced AI tools streamlines your path to market access in over 30 countries. Don't let regulatory hurdles block your growth in LATAM. Contact us today at [email protected] or visit https://pureglobal.com/ to learn how we can accelerate your success.

This week, we dissect the groundbreaking new resolution from Brazil's ANVISA, RDC 989, which establishes a new fast-track approval pathway for AI-driven diagnostic software. This is a pivotal moment for the MedTech industry in Latin America, promising to accelerate innovation and market access. However, this opportunity comes with significant new hurdles. The regulation introduces complex requirements for predetermined change control plans, mandates the use of local Brazilian patient data for algorithm validation, and enforces stricter cybersecurity protocols. We explore the strategic implications for foreign and domestic manufacturers aiming to capitalize on this new landscape. A real-world example. a U.S.-based SaMD company has its AI-powered radiological tool approved by the FDA. They targeted Brazil for their next expansion, but ANVISA's new RDC 989 just made their existing clinical data insufficient. They now face the urgent challenge of conducting a local validation study to qualify for the fast-track process, a costly and time-consuming roadblock they didn't anticipate. Key Takeaways: 1. What exactly is a Predetermined Change Control Plan (PCCP) and how do I create one for ANVISA? 2. Does my existing clinical data from US or EU studies meet the new requirements for Brazil? 3. What are the specific cybersecurity and data privacy mandates under RDC 989? 4. How can I initiate a local clinical validation study in Brazil efficiently? 5. What is the timeline for compliance for products already under review by ANVISA? 6. How does this new fast-track pathway change the overall cost and timeline for market entry? 7. Will this regulation give local Brazilian MedTech startups a competitive advantage? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI and data tools to streamline global market access, helping you navigate complex regulations like RDC 989 to ensure your products reach the market efficiently. To understand how we can help with your market access strategy in Brazil and beyond, contact us at [email protected] or visit https://pureglobal.com/.

Brazil's national regulatory agency, ANVISA, has unexpectedly accelerated the compliance deadlines for its Unique Device Identification (UDI) system, creating a significant new challenge for MedTech manufacturers. This sudden shift requires immediate action on labeling, data management, and submission strategies to avoid market disruption. While this presents a major hurdle, it also offers a competitive advantage to agile companies that can quickly adapt. This episode of LATAM MedTech Insights explores the specific details of ANVISA's new mandate, the potential pitfalls, and the strategic opportunities that arise from this regulatory surprise. **Case Study:** Imagine your company has a portfolio of high-risk cardiovascular devices thriving in the Brazilian market. Your team has been methodically preparing for a 2027 UDI compliance deadline. Suddenly, last week's ANVISA announcement pulls that deadline forward, demanding full compliance in just 18 months. Now you face an urgent crisis: redesigning all packaging, gathering extensive new data points, and navigating a complex database submission, all while your competitors are facing the same race against time. A single misstep could mean losing your registration and handing the market to a more prepared rival. **Key Takeaways:** * What are the exact new UDI compliance deadlines for different device classes in Brazil? * Why are the new data submission requirements more complex than just standard labeling? * How can this regulatory shift completely disrupt your current product roadmap and budget? * What are the immediate operational steps your company must take to avoid a market lockout? * Could this move by ANVISA trigger similar accelerated timelines in other LATAM countries? * Is your current local representative in Brazil equipped to handle this sudden change? * How can you turn this compliance crisis into a strategic advantage over your competitors? Struggling to make sense of new regulations in Latin America? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise in markets like Brazil with advanced AI tools to streamline your global market access, from regulatory strategy to technical dossier submission. Don't navigate the complexities alone. Contact Pure Global at [email protected] or visit https://pureglobal.com/ to secure your market presence.

This week, we dissect a sudden and significant regulatory enforcement shift from Brazil's ANVISA. The agency has accelerated the implementation of its comprehensive UDI traceability system for high-risk medical devices, a key part of its 2026-2027 agenda to harmonize with global standards. This move is catching many international manufacturers off guard, creating immediate challenges for market access and post-market compliance. We explore the concrete implications of this accelerated timeline, from rejected submissions due to data inconsistencies to new, stringent requirements for adverse event reporting. Consider a company that has spent years preparing its Class IV device for the Brazilian market. They believe their dossier is perfect, but their submission is rejected on day one. The reason is not a failure in the device's clinical data, but an administrative error in the UDI database submission, a new and complex requirement. This single misstep could delay their launch by over six months, costing millions in potential revenue. **Key Takeaways:** * What are the exact database requirements for the new UDI submissions under ANVISA's accelerated timeline? * How does this UDI enforcement align with the broader EU MDR harmonization trend in Brazil? * Which specific device classes are most at risk for submission delays right now? * What are the new post-market surveillance reporting requirements involving UDI data? * How can you validate your UDI data for ANVISA's system before making a formal submission? * What are the most common mistakes manufacturers are making with the new UDI requirements? * How should this change impact your budget and timeline for entering the Brazilian market? Navigating unexpected regulatory hurdles like these is where Pure Global excels. We provide end-to-end regulatory consulting for MedTech and IVD companies, leveraging our local expertise in Brazil and over 30 other markets. From developing an updated regulatory strategy to managing complex database submissions and ensuring post-market compliance, we streamline your path to market. Don't let regulatory surprises derail your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to secure your market access.

Brazil's regulatory agency, ANVISA, is launching a major digital overhaul for 2026, promising to slash approval times and streamline market access for medical devices. This episode dives into the core of ANVISA's new agenda, from the 'AnvisAI' project aimed at modernizing submissions to new fast-track queues for lower-risk devices. We explore how this digital transformation is creating unprecedented opportunities for MedTech innovators. For instance, a company with a cutting-edge AI diagnostic tool that once faced a multi-year waiting period now sees a viable path to market, evidenced by recent approvals of complex software. But this new speed comes with higher expectations, demanding alignment with stringent global standards. Key Questions This Episode Will Address: - How will ANVISA's 2026 digital agenda change your market entry strategy for Brazil? - Is your current technical dossier prepared for the new, stricter compliance framework? - What are the hidden risks of misclassifying your software under the new accelerated pathways? - How can the recent approval of AI imaging software serve as a roadmap for your submission? - Are you prepared to leverage these regulatory changes to get ahead of your competitors in LATAM's largest market? - What specific steps must you take to adapt your Quality Management System for Brazil's new landscape? At Pure Global, we provide end-to-end regulatory consulting to help MedTech and IVD companies navigate this evolving environment. We combine local expertise with advanced AI tools to streamline global market access. Let us be your local representative and strategic partner in over 30 markets. Contact us for a consultation at [email protected] or visit https://pureglobal.com/.

This week on LATAM MedTech Insights, we dissect the groundbreaking news from Brazil's ANVISA. A new fast-track approval pathway for AI-powered medical software has just been announced, promising to revolutionize market access in Latin America's largest market. This is the opportunity the industry has been waiting for, but it comes with a complex twist. This newfound speed is coupled with a formidable set of new cybersecurity and data privacy mandates, tailor-made for Brazil. We explore the hidden hurdles within this new regulation that could trip up even the most prepared global MedTech firms, turning a golden opportunity into a costly and time-consuming dead end. Here is a real-world scenario. Your company has developed a breakthrough AI diagnostic tool, and you are ready to conquer the Brazilian market. The new fast-track promises a swift approval, but your application is suddenly stalled. The reason? You overlooked an obscure new requirement for a Brazil-based Data Protection Officer, a critical detail buried deep in the new regulation. Now you face months of delays, unforeseen costs to restructure your local operations, and the constant threat of a competitor beating you to market. Key Takeaways for This Episode: - What are the specific device classifications that qualify for ANVISA's new SaMD fast-track? - How do the new Brazilian data privacy rules for MedTech differ from GDPR and HIPAA? - Is a local, Brazil-based Data Protection Officer now mandatory for all foreign SaMD manufacturers? - What are the three biggest cybersecurity vulnerabilities ANVISA will be auditing for in new submissions? - How can you leverage your existing technical dossier for this new, unique submission process? - What are the new requirements for post-market algorithm performance monitoring? - Could this new Brazilian framework become the regulatory blueprint for other LATAM countries? Navigating these regulatory shifts is what we do best. Pure Global transforms complexity into a competitive advantage. With our on-the-ground experts in Brazil and advanced AI-powered data tools, we provide end-to-end solutions for market access, from initial strategy and technical dossier submission to acting as your official local representative. Don't let regulatory hurdles block your entry into LATAM's most dynamic market. To ensure your AI MedTech product successfully navigates the new ANVISA landscape, contact us at [email protected] or visit https://pureglobal.com/ for a strategic consultation.

In a move that sent shockwaves through the MedTech industry, Brazil's regulatory agency, ANVISA, launched a mandatory new digital submission platform for high-risk medical devices last week. This sudden shift away from traditional paper-based systems has left many manufacturers scrambling to adapt. This episode of LATAM MedTech Insights unpacks the immediate fallout of this decision. We explore the technical hurdles, the hidden documentation requirements, and the strategic implications for companies aiming to enter or expand within Latin America's largest market. We'll look at the case of a cardiovascular device company whose critical product launch was jeopardized overnight by the new digital mandate. Their story highlights the severe financial and strategic costs of being unprepared for abrupt regulatory changes in Brazil. Key Questions Answered: 1. What are the three biggest technical mistakes companies make on the new ANVISA portal? 2. How does this digital shift affect submission timelines for Class III and IV devices? 3. Are there any unannounced changes to the technical dossier requirements? 4. How can you leverage this change to potentially speed up your approval process? 5. What does this move signal about ANVISA's long-term regulatory strategy? 6. Is your local distributor truly equipped to handle this level of regulatory complexity? 7. How will this impact foreign manufacturers compared to local Brazilian companies? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions for MedTech and IVD companies, acting as your local representative and using advanced AI tools to streamline technical submissions. Don't let regulatory surprises derail your market access strategy. Contact us for a consultation at [email protected] or learn more by visiting https://pureglobal.com/.

This week, we dive into a critical regulatory update from Brazil's ANVISA that is reshaping the landscape for digital health and Software as a Medical Device (SaMD). The new guidance introduces stringent requirements for AI technologies, cybersecurity, and local data management, catching many international MedTech companies off guard. We explore why existing FDA or CE Mark documentation is no longer enough for the Brazilian market. This episode breaks down the new rules and discusses how adapting to them can provide a significant competitive advantage in Latin America's largest and most lucrative MedTech market. **Case Study:** A U.S. startup with a cutting-edge AI diagnostic tool was poised to launch in Brazil. Despite having their clinical data and technical file ready, their submission was abruptly halted. The reason? It lacked a detailed cybersecurity vulnerability report adapted to Brazil's specific data privacy laws (LGPD). This unexpected roadblock could delay their launch by over a year, creating an opening for local competitors to seize market share. Are you prepared for this new reality? **Key Questions Answered:** * What specific cybersecurity standards has ANVISA now mandated for all SaMD products? * How does the new guidance re-classify your AI-powered medical software? * Are your existing clinical validation studies sufficient for the new Brazilian requirements? * What are the three most common documentation pitfalls for foreign firms under the new guidelines? * Why is appointing a local Brazil Registration Holder now more critical than ever? * How can you turn Brazil's tough new regulations into a strategic advantage? At Pure Global, we specialize in demystifying complex regulatory landscapes. Our local experts in Brazil, combined with our AI-driven data tools, provide end-to-end support for your MedTech and IVD products. We transform regulatory hurdles into market opportunities. Ready to accelerate your entry into Brazil? Contact us at [email protected] or visit https://pureglobal.com/.

This week on LATAM MedTech Insights, we explore the significant shift in Latin America's medical device industry. The region is rapidly moving from being a net importer to a powerful hub for local MedTech manufacturing. We unpack the key drivers behind this acceleration, including supply chain strategy, cost benefits, and new government incentives in major markets like Brazil and Mexico. We dive into the real-world challenges and opportunities this trend presents. We analyze the complex decision-making process for companies weighing the benefits of local production against the formidable regulatory hurdles set by agencies like ANVISA and COFEPRIS. It's a strategic gamble that could redefine market leadership in the region. What you'll learn in this episode: - Why are multinational MedTech companies suddenly prioritizing local manufacturing in Latin America? - What are the hidden regulatory costs of setting up a production line in Brazil versus Mexico? - How can a company leverage local manufacturing to gain a competitive advantage? - What is the number one mistake companies make when aligning with ANVISA's manufacturing practices? - Are local supplier networks in countries like Colombia and Costa Rica mature enough for complex devices? - How does in-country production change the strategy for post-market surveillance? - What specific government incentives are most attractive for new MedTech manufacturers in 2026? Navigating the transition to local manufacturing requires deep, on-the-ground expertise. Pure Global offers end-to-end regulatory solutions for MedTech companies, combining local experts with advanced AI tools to streamline market access. Whether you're developing a regulatory strategy for a new plant or registering your locally produced device, we act as your local representative in over 30 markets, including Brazil, Mexico, and Colombia. Let us help you turn complex regulatory challenges into a competitive advantage. Contact us at [email protected] or visit https://pureglobal.com/.

Brazil's health agency, ANVISA, has just introduced a stringent new cybersecurity regulation for all connected medical devices. This sudden move, aimed at enhancing patient safety and data protection, presents immediate and complex challenges for manufacturers. It escalates compliance costs and extends timelines, demanding a new level of technical documentation that many were not prepared for. This podcast episode breaks down what the new rules demand and explores the strategic implications for companies operating in Latin America's largest market. We analyze the specific requirements, the reasons behind this abrupt shift, and how it will reshape the competitive landscape for both local and international MedTech firms. **Key Takeaways:** * What are the three core technical requirements of ANVISA's new cybersecurity rule? * How does this new mandate affect devices already on the Brazilian market versus new submissions? * Why is this change happening now, and is it part of a larger LATAM regulatory trend? * What are the biggest compliance blind spots for foreign manufacturers entering Brazil? * Can proactive compliance with this new rule become a competitive advantage? * How will this impact the device registration timeline and budget for 2026? * What specific documentation, like a Software Bill of Materials, is now non-negotiable? Is your MedTech device ready for Brazil's new cybersecurity landscape? At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies. We combine local expertise with advanced AI to streamline your market access and ensure you stay ahead of critical changes like this. Don't let regulatory surprises derail your strategy. Contact Pure Global at [email protected] or visit us at https://pureglobal.com/.

This week, we dissect a groundbreaking regulatory shift in Latin America's largest market. Brazil's ANVISA has just unveiled a new, accelerated pathway for high-risk medical devices by recognizing approvals from major global agencies, signaling a major push to attract cutting-edge technology. But this speed comes with a hidden cost. The new framework also introduces some of the strictest post-market surveillance demands seen in the region. We explore the critical balance between rapid innovation and patient safety, and what this means for MedTech companies eyeing the Brazilian market. Imagine your company's AI-powered surgical device received FDA approval and can now use a fast-track process for Brazil. You cut your time-to-market by more than a year, but now ANVISA is demanding real-world performance data from Brazilian hospitals to validate its effectiveness locally. How do you leverage the speed of entry without getting buried in this new, intensive compliance burden? Key Takeaways: - What is the AREE reliance pathway and which foreign approvals does ANVISA now recognize? - How does this new rule change the submission strategy for Class III and IV devices in Brazil? - What are the unwritten expectations for post-market surveillance for fast-tracked devices? - How can you prepare a real-world data collection plan for the Brazilian market? - Does this regulatory shift in Brazil signal a wider trend across Latin America? - What are the biggest compliance risks for companies under this new paradigm? - How do you manage technical dossier requirements when leveraging a foreign approval? - What are the key operational costs associated with these new post-market rules? At Pure Global, we specialize in navigating these complex regulatory shifts. Our combination of local expertise and advanced AI tools helps MedTech and IVD companies streamline market access, from initial strategy to post-market surveillance. We turn regulatory hurdles into opportunities for growth. To learn how we can help you succeed in Brazil and over 30 other markets, contact us at [email protected] or visit https://pureglobal.com/.

This week, we dive into a critical regulatory update from Brazil. ANVISA has just rolled out a new resolution that reshapes the essential safety and performance requirements for medical devices, placing a heavy new emphasis on lifecycle risk management and international harmonization. This change impacts everything from technical file preparation to post-market surveillance. We explore the specific new requirements for high-risk devices, software, and the increased demand for locally relevant clinical data. This episode is essential for any MedTech company currently in or planning to enter the Brazilian market, as non-compliance with these new rules could lead to significant delays and rejections. **Case Study:** A European MedTech company, confident with their CE-marked cardiac monitoring software, submits to ANVISA. They are unexpectedly rejected. The reason? Their risk management file, which was perfectly acceptable for the EU, failed to meet Brazil's new, stringent requirements for post-market data collection and cybersecurity vulnerability monitoring. Their market entry is now delayed by at least a year, forcing a costly overhaul of their compliance documentation. **What You'll Learn:** - What specific event triggered ANVISA's major regulatory overhaul last week? - How does the new 'lifecycle' approach to risk management change your submission strategy? - Are your existing international clinical studies still valid under the new rules? - What are the three new documentation requirements for Software as a Medical Device (SaMD)? - Why might your current Quality Management System be non-compliant in Brazil right now? - What is the single biggest mistake foreign manufacturers are making in their new ANVISA submissions? At Pure Global, we specialize in navigating these complex regulatory landscapes. We offer end-to-end solutions, from market access strategy to local representation, using advanced data tools to streamline your path to compliance in over 30 markets, including Brazil. Don't let regulatory hurdles block your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can help.

This week, we dive into a landmark regulatory shift in Brazil. ANVISA has just launched a new, expedited approval pathway for AI-powered medical software, potentially slashing market entry timelines. This episode breaks down the immense opportunity this presents for MedTech innovators looking to enter Latin America's largest market. But there's a critical catch. This accelerated access comes with a new, aggressive post-market surveillance system that demands continuous real-world data reporting. We explore this paradox: while the front door is easier to open, the rules for staying inside have become far more complex. We discuss what this means for manufacturers, from operational burdens to the risk of registration suspension. **Key Takeaways:** * What specific change did ANVISA just implement for AI-powered medical software? * Why is faster approval only half the story for manufacturers entering Brazil? * What are the new, stringent quarterly data reporting requirements? * How does this shift the regulatory burden from pre-market to post-market? * What kind of operational systems must companies now build to ensure compliance? * Which foreign approvals can be leveraged for this new fast-track process? * Could this new Brazilian model become a blueprint for other LATAM countries? At Pure Global, we specialize in navigating these complex regulatory landscapes. From initial market strategy and registration to fulfilling rigorous post-market surveillance requirements, our local experts and advanced AI tools ensure you can access and maintain your presence in over 30 global markets, including Brazil. Get in touch with us to future-proof your MedTech products in Latin America. Contact us at [email protected] or visit https://pureglobal.com/.

This week on LATAM MedTech Insights, we analyze the seismic new draft regulation from Brazil's ANVISA that is set to overhaul the rules for Software as a Medical Device (SaMD). This proposal introduces stringent new requirements for AI technologies and local data management, promising to reshape market access for all foreign MedTech companies targeting Brazil. We dive into the real-world impact by examining the case of a European AI diagnostics firm. Their expansion strategy, once clear, is now facing critical roadblocks due to unexpected demands for in-country clinical studies and data hosting, threatening significant delays and cost overruns. This story is a crucial lesson for any innovator looking to enter Latin America's most complex market. Key Takeaways: - Why is ANVISA suddenly proposing a major revision to its two-year-old SaMD regulation? - What are the specific new cybersecurity and data hosting rules for AI medical devices? - Will your existing FDA clearance or CE Mark still be enough for your software registration in Brazil? - What defines a "representative Brazilian population" for the new mandatory clinical validation studies? - How can you submit feedback on this draft regulation before it becomes law? - What strategies can turn these new regulatory barriers into a competitive advantage? - How should this change affect your company's five-year expansion plan for Latin America? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced AI tools to streamline global market access. Whether you are navigating new draft regulations or planning a multi-market launch, we build efficient pathways for your products. Confused about the new ANVISA rules? Contact us at [email protected] or visit https://pureglobal.com/ for a strategic consultation.

Brazil's regulatory agency, ANVISA, has just rolled out game-changing new rules that create a fast-track pathway for high-risk medical devices. This episode breaks down the new "reliance" mechanism that allows manufacturers to use existing international approvals for quicker market access, and what the new clinical trial law means for MedTech innovation. We explore how these changes are dismantling long-standing barriers to entry in Latin America's largest market. For any company with an advanced medical device, what was once a multi-year waiting game has just become a strategic race. We discuss how this impacts market entry strategy, cost, and the overall opportunity in Brazil. --- **This Episode's Deep Dive:** Consider a US-based company with an innovative cardiovascular implant (a Class IV device) with full FDA approval. The pain point for them has always been the Brazilian market entry: a separate, two-to-three-year ANVISA review process, huge costs, and unpredictable timelines. Now, with the new reliance pathway, that entire calculus has changed. They can leverage their existing FDA clearance to potentially secure Brazilian registration in under a year, turning a long-term aspiration into an immediate strategic possibility. --- **Key Takeaways (本期干货):** * What exactly is ANVISA's new reliance pathway and does my product qualify? * How does this regulatory shortcut change the ROI calculation for entering Brazil? * Which specific international approvals (like FDA, CE) are recognized for this process? * What are the critical documentation requirements for a successful reliance submission? * Beyond reliance, how does Brazil's new clinical trial law affect our global R&D strategy? * Are there any hidden complexities or potential pitfalls in this new accelerated process? * How should our regulatory team adapt its strategy to capitalize on this change now? --- At Pure Global, we specialize in turning complex regulatory changes into market opportunities. Our local experts in Brazil and our AI-powered data tools provide end-to-end support, from developing the optimal reliance strategy to managing your submission with ANVISA. We help you navigate the new landscape efficiently to accelerate your market access. To learn more about how we can help you successfully launch your MedTech or IVD products in Brazil and over 30 other markets, contact us at [email protected] or visit https://pureglobal.com/.

In this episode, we dissect the groundbreaking news from Brazil's health agency, ANVISA. Last week, they launched "Agiliza IA Saúde," a new fast-track approval program for AI-powered medical software. This move could unlock massive opportunities in Latin America's largest market, promising to slash registration times for innovative diagnostic technologies. While the opportunity is immense, it comes with a critical challenge. The fast-track is gated by a strict compliance audit tied to Brazil's stringent data protection law, the LGPD. This has created a hidden barrier for international companies who are unprepared for the deep level of data traceability and AI "explainability" that ANVISA now requires, potentially derailing their market entry strategies. **Featured Case:** A European MedTech scale-up with a market-leading AI diagnostic tool saw Brazil's new program as their golden ticket into LATAM. They were ready for a full-scale launch but were stopped cold during the pre-submission phase. Their pain point: they could not adequately prove compliance with LGPD's data processing and localization requirements, a detail they had completely overlooked. Their entire expansion timeline is now on hold, forcing a costly redevelopment of their data governance framework. **Key Takeaways From This Episode:** * What are the specific eligibility criteria for ANVISA's new AI software fast-track program? * How does Brazil's data protection law (LGPD) directly create new challenges for SaMD manufacturers? * What is the "right to explanation" and how does it impact AI-based medical devices? * What are the most common compliance mistakes foreign companies make when entering the Brazilian market? * Is this new ANVISA policy a sign of a wider regulatory trend across Latin America? * How can you build a regulatory strategy that balances speed-to-market with deep compliance? * What level of data traceability and cybersecurity is now considered the standard for Brazil? Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise in markets like Brazil with advanced AI tools to streamline global market access. We help you navigate complex requirements like ANVISA's new program to ensure a fast and successful launch. To learn more, contact us at [email protected] or visit us at https://pureglobal.com/.

This week, we dissect the groundbreaking new cybersecurity resolution from Brazil's ANVISA that is sending ripples through the MedTech world. The new rules for Software as a Medical Device (SaMD) go far beyond international standards, demanding a proactive, localized approach to cybersecurity and data validation that presents both challenges and opportunities. We explore how this regulation transforms the compliance burden, requiring continuous threat monitoring and incident reporting tailored specifically for the Brazilian market. This is no longer a simple paperwork exercise; it's a fundamental shift in how MedTech companies must manage their products' lifecycle in Latin America. A case in point: An EU-based scaleup, with a fully CE-marked AI diagnostic software, initiated their Brazilian market entry, assuming a smooth process. They were stalled for nine months. The reason? ANVISA's new rule required them to prove their algorithm's efficacy and lack of bias using a specific, anonymized dataset from three different Brazilian states, a requirement not explicitly detailed in the main resolution but enforced during the technical review. This unforeseen obstacle forced them into costly and time-consuming local clinical partnerships, delaying their revenue generation by almost a year. Key takeaways from this episode: - How does ANVISA's new lifecycle approach to cybersecurity change your post-market surveillance duties? - Are your global cybersecurity incident response plans sufficient for Brazil's new 72-hour reporting rule? - What are the new, unwritten rules for validating your AI or ML algorithm with local Brazilian patient data? - Why might your existing international technical dossier now be rejected by ANVISA? - How can you turn these stringent data requirements into a competitive advantage in the Brazilian market? - What specific documentation is now required to prove your software's resilience against cyber threats? - How will this new regulation impact market access timelines and costs for foreign SaMD manufacturers? Pure Global offers end-to-end regulatory consulting to help MedTech and IVD companies navigate these complexities. From developing a robust regulatory strategy and compiling a compliant technical dossier to acting as your official local representative, we streamline global market access. Our expertise, combined with advanced AI tools, ensures you can meet demanding local requirements efficiently. Don't let regulatory surprises derail your launch. Contact us at [email protected] or visit https://pureglobal.com/ to secure your market presence in Brazil.

This week on LATAM MedTech Insights, we dissect the groundbreaking new Software as a Medical Device (SaMD) regulation just released by Brazil's ANVISA. This isn't just another update; it's a complete strategic reset for any digital health company targeting the Brazilian market. We explore the critical changes in risk classification for AI-driven software and the stringent new cybersecurity mandates that have just come into effect. Imagine a cutting-edge European AI diagnostics startup, poised to enter Brazil as its gateway to Latin America. Last week, their entire market access strategy was invalidated by ANVISA's new resolution. Their product's classification has jumped from low-risk to high-risk, demanding extensive clinical data they haven't prepared for. This episode details the pivots and strategies companies in this exact situation must now consider. Key Takeaways: 1. What specific event triggered ANVISA's major overhaul of its SaMD regulations? 2. How do the new AI risk classifications diverge from established FDA or EU guidelines? 3. What are the most overlooked cybersecurity requirements in the new Brazilian framework? 4. For SaMDs now classified as high-risk, what are the specific clinical evidence demands? 5. How will this regulatory shift impact foreign investment in Brazil's digital health sector? 6. Are there any provisions for legacy software already on the market? 7. What new documentation for data privacy is now mandatory for submission? Navigating this new landscape is complex, but Pure Global is built for this challenge. We offer end-to-end regulatory consulting, using our local Brazilian expertise and advanced AI tools to streamline your path to market. From developing a new regulatory strategy to compiling your technical dossier for ANVISA, we ensure your innovation meets these new standards efficiently. Don't let regulatory shifts derail your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to secure your market access.

This week, we dissect the groundbreaking new resolution from Brazil's ANVISA that's set to revolutionize the AI-powered medical device landscape. We explore how this regulatory shift dramatically accelerates market access for Software as a Medical Device (SaMD) companies. Learn what this means for startups and established players eyeing the largest MedTech market in Latin America, and how the rules have fundamentally changed for innovators who were previously locked out by slow, hardware-focused regulations. A real-world pain point: Imagine spending two years and hundreds of thousands of dollars trying to get your innovative diagnostic AI approved in Brazil, only to be stuck in a regulatory framework designed for physical hardware. That was the reality. We discuss how the new rules directly address this critical pain point, potentially turning a 24-month nightmare into a 6-month opportunity. Key Takeaways: * What specific changes did ANVISA just implement for AI medical software? * How does the new risk classification system impact my product's registration timeline? * Which types of AI devices benefit the most from this fast-track process? * Is this a signal for other LATAM regulators like COFEPRIS or INVIMA to follow? * What are the immediate steps my company should take to leverage this opportunity? * Are there any hidden compliance traps in the new Brazilian regulations? * How can foreign companies navigate the updated submission process effectively? At Pure Global, we specialize in navigating these complex regulatory shifts. Our combination of local expertise in Brazil and advanced AI tools can streamline your market access strategy under these new rules. For end-to-end regulatory consulting for MedTech and IVD companies, contact us at [email protected] or visit https://pureglobal.com/.

Brazil's medical device market has undergone its most significant regulatory overhaul in two decades with the full implementation of RDC 751/2022. This new framework replaces the long-standing RDC 185/2001, introducing a new risk classification system and technical documentation structure that aligns more closely with global standards like the EU MDR. While this harmonization presents long-term benefits, the immediate transition creates critical challenges for MedTech manufacturers. Companies must now navigate new submission pathways, restructure their technical dossiers to meet IMDRF standards, and ensure their labeling and post-market activities are fully compliant, facing risks of rejection and market access delays if unprepared. A US-based scaleup, planning a routine renewal for their Class II device in Brazil, recently discovered their existing technical file was obsolete under RDC 751. They are now facing a complete dossier overhaul and the risk of a gap in their market authorization, jeopardizing a key distribution contract and threatening their revenue stream in the region. What You'll Learn: - How does the new four-class risk system in Brazil impact your existing product portfolio? - What are the critical differences between the old submission process and the new technical dossier requirements? - Is your current product labeling and IFU compliant with the latest ANVISA updates? - What are the most common rejection points for submissions under the new RDC 751? - How can leveraging your EU MDR documentation give you a head start in Brazil? - What specific post-market surveillance changes must you implement immediately? - Are there any critical transition deadlines you might have missed? Pure Global offers end-to-end regulatory consulting to navigate these complex changes. We combine local expertise in Brazil with advanced AI tools to streamline your market access. Don't let regulatory shifts disrupt your strategy. Contact Pure Global at [email protected] or visit us at https://pureglobal.com/ for a consultation.

This week on LATAM MedTech Insights, we dissect the immediate impact of a surprise guidance note issued by Brazil's ANVISA. This new clarification on regulation RDC 751 is tightening the screws on foreign medical device manufacturers, especially those in the digital health and SaMD space. We explore the heightened requirements for technical dossiers and clinical data that are catching companies off guard. Discover why your existing FDA or CE mark documentation may no longer be enough for the Brazilian market. We use the real-world example of an AI diagnostic company suddenly facing major delays and costs, highlighting the critical need for a proactive and localized regulatory strategy to avoid common pitfalls. Key questions from this episode: - What specific change in ANVISA’s enforcement of RDC 751 caught the industry by surprise last week? - Why is foreign clinical data now facing greater scrutiny for SaMD submissions in Brazil? - How has the role of the Brazil Registration Holder (BRH) shifted from a legal formality to a critical strategic partner? - What are the three biggest mistakes manufacturers make when preparing their technical dossier for ANVISA? - Is Brazil's regulatory landscape becoming a barrier or an opportunity for high-quality MedTech? - Could your device's cybersecurity protocols be the hidden factor that leads to rejection? - How do you demonstrate clinical applicability to Brazil's diverse population without running entirely new trials? Navigating complex regulatory shifts like this is what we do best. Pure Global offers end-to-end solutions for MedTech companies, combining local experts in Brazil with advanced AI tools to streamline your path to market. From regulatory strategy and local representation to compiling your technical dossier, we ensure you're prepared for ANVISA's toughest questions. Don't let regulatory hurdles block your entry into Latin America's top market. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

Brazil's digital health market is booming, but a recent regulatory update from its agency, ANVISA, has changed the rules of the game for 2026. The new guidance for Software as a Medical Device (SaMD) goes far beyond basic registration, introducing stringent cybersecurity and lifecycle management requirements that are catching many international companies off guard. In this episode, we break down what these changes mean for you. We explore why your existing FDA or CE Mark documentation is no longer sufficient for Brazil and how adapting to these new rules can become your key competitive advantage in Latin America's largest market. **Case Study:** Imagine your company has a cutting-edge AI diagnostic tool, ready to conquer the Brazilian market. You’ve prepared your clinical data, but you suddenly face a rejection because your submission lacks a detailed cybersecurity vulnerability report adapted to Brazil's data privacy laws (LGPD). This unexpected roadblock could delay your launch by over a year, allowing local competitors to capture the market first. Are you prepared for this new reality? **Key questions answered in this episode:** * What specific cybersecurity standards has ANVISA recently mandated for SaMD? * How can you leverage your existing technical file for a successful Brazilian submission? * What are the three most common pitfalls for foreign firms under the new guidelines? * Why is post-market surveillance now as critical as the initial registration? * How does Brazil's new framework signal a larger regulatory trend across LATAM? * What is the crucial first step to take before submitting your digital health product to ANVISA? At Pure Global, we specialize in demystifying these complex regulatory landscapes. Our local experts in Brazil, combined with our AI-driven data tools, provide end-to-end support for your MedTech and IVD products. We transform regulatory hurdles into market opportunities. Ready to accelerate your entry into Brazil? Contact us at [email protected] or visit https://pureglobal.com/.

This episode of LATAM MedTech Insights dives into the critical new regulatory guidance from Brazil's ANVISA for Software as a Medical Device (SaMD). As Brazil doubles down on localized requirements, we explore why simply having FDA or CE approval is no longer enough to guarantee market access. We uncover the hidden complexities of ANVISA's risk classification and the growing importance of local data and cybersecurity compliance. We examine a case study of a digital health company whose market launch was delayed by nine months due to unexpected data privacy requirements. This costly setback highlights a critical pain point: underestimating Brazil's unique regulatory interpretation can derail your entire market entry strategy, even with a globally successful product. Key Questions Answered: - Is ANVISA's evolving SaMD framework a hidden barrier or a clear pathway for prepared companies? - How can your SaMD's risk classification unexpectedly change when entering Brazil? - What are the three most common LGPD (Brazil's Data Protection Law) mistakes foreign MedTech firms make? - Why is your choice of a local Brazil Registration Holder (BRH) more critical than ever for software devices? - What post-market surveillance strategies for SaMD will satisfy ANVISA's new focus? - How can you leverage your existing clinical data for the Brazilian market without starting from scratch? Navigating global markets requires more than just a great product; it demands expert regulatory strategy. Pure Global offers end-to-end solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline market access in over 30 countries, including Brazil. Whether you're a startup or a multinational, we are your local representative, ensuring a clear path to registration and post-market compliance. Don't let regulatory hurdles block your growth. Contact us at [email protected] or visit https://pureglobal.com to learn more.

Brazil's regulatory landscape for AI and software medical devices just got a lot more complex. In this episode, Pure Global dives into ANVISA's latest unspoken rules that demand localized clinical data and stricter adherence to Brazil's data privacy laws, moving beyond simple acceptance of FDA or CE marks. We explore why your existing global dossiers might now be insufficient for the Brazilian market. We break down the new expectations for cybersecurity and the critical importance of validating your technology on local patient populations to ensure a successful product registration. **Case Study:** A U.S. diagnostics firm with a breakthrough AI-powered imaging tool had their Brazilian market entry delayed by six months. Their mistake? They submitted their FDA-cleared validation package without a supplemental study on a Brazilian patient cohort, leading to a cascade of questions from ANVISA that brought their launch to a halt. **Key Takeaways:** * Why is ANVISA now looking beyond FDA and CE approvals for SaMD? * What specific type of local clinical data can make or break your AI device submission in Brazil? * How can Brazil's data privacy law (LGPD) unexpectedly block your medical device approval? * What are the new cybersecurity vulnerabilities ANVISA is actively screening for? * Is it possible to use this regulatory shift to gain an advantage over slower competitors? * What is the number one assumption foreign companies make that leads to rejection? Struggling to keep up with the fast-paced changes in LATAM's regulatory landscape? Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI tools to streamline your market access. We act as your local representative, manage technical submissions, and ensure post-market compliance. Don't let regulatory hurdles block your expansion. Contact us for a strategic consultation at [email protected] or visit us at https://pureglobal.com/.

This week, we dive into a sudden and impactful regulatory shift in Brazil. ANVISA, the country's health agency, released a new resolution last week that specifically targets Software as a Medical Device (SaMD), creating significant new hurdles for manufacturers, especially those using AI and machine learning. This update introduces stringent cybersecurity protocols, challenging data localization laws, and a more rigid process for software updates. We explore what these changes mean on the ground through a practical case study. A U.S. diagnostics company, on the verge of launching its FDA-cleared AI cardiac software in Brazil, now finds its entire market entry strategy jeopardized by these new rules. Their reliance on U.S.-based cloud servers and agile development cycles directly conflicts with ANVISA's new mandates, forcing them to consider a costly strategic pivot or abandon the market. Key Takeaways: - What are the three core pillars of ANVISA's new SaMD regulation announced last week? - Why is the new data sovereignty rule a major obstacle for global MedTech companies? - How does the updated change control process impact companies using agile development? - What specific cybersecurity standards are now mandatory for software devices in Brazil? - Can you still leverage your FDA or CE marking for an expedited review under these new rules? - What is the first step you should take if your product is affected by this sudden change? Navigating the complexities of LATAM's regulatory environment is critical for success. At Pure Global, we offer end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline global market access. Whether you're dealing with new software regulations in Brazil or planning a multi-market launch, we provide the strategic guidance and in-country representation you need. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

In this episode, we dissect the breaking news from Brazil where the regulatory agency, ANVISA, has just rolled out a comprehensive and stricter framework for AI-powered Software as a Medical Device (SaMD). This sudden move creates significant new barriers to entry in Latin America's most lucrative MedTech market. We explore the immediate and costly implications for international manufacturers, whose existing global dossiers and market-entry strategies may now be insufficient. We use the real-world example of a company poised to launch its innovative diagnostic software, only to be stopped in its tracks by a new, unexpected demand for local clinical data and cybersecurity compliance, forcing a difficult decision between a costly new trial or abandoning the market. Key Takeaways: - What are the three most critical changes in ANVISA's new SaMD regulation? - Why is Brazil now demanding local clinical data for AI algorithm validation? - How does this new framework impact your existing device classification and submission strategy? - What specific cybersecurity protocols are now mandatory for market access? - Can your existing technical file from the US or EU be leveraged, or must you start from scratch? - What are the hidden costs and timelines associated with this new regulation? - How can you turn this regulatory hurdle into a long-term competitive advantage in the LATAM region? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI tools to streamline global market access. We act as your local representative in Brazil and over 30 other markets, developing efficient pathways for regulatory approval. Turn regulatory complexity into a strategic advantage. Contact us at [email protected] or visit https://pureglobal.com/.

Mexico just opened a new door for MedTech companies. Last week, the country's health authority, COFEPRIS, launched an accelerated approval pathway for devices with existing FDA or CE credentials. This could slash market entry timelines from years to months, but it comes with a catch. This episode dives deep into the opportunities and the hidden compliance traps of this new regulation. We uncover the specific requirements for data privacy and cybersecurity that are unique to Mexico, creating unforeseen challenges for even the most prepared global firms. A US-based company with an innovative, FDA-cleared diagnostic tool sees the news from Mexico and rushes to apply through the new fast-track system. They submit their existing technical file, assuming their robust cybersecurity measures will suffice. Two months later, their application is stalled. The reason: their documentation fails to address Mexico’s specific laws on patient data rights, a nuance they completely overlooked. Now they face significant delays and the costly process of redrafting their submission. Key Questions from this Episode: * Is your medical device eligible for Mexico's new fast-track approval pathway? * What specific documentation from your FDA or CE submission will COFEPRIS accept? * Why is the new 'Cybersecurity and Data Privacy Addendum' the most critical new hurdle? * How do Mexico's data protection laws for medical devices differ from HIPAA and GDPR? * What are the common pitfalls that can lead to rejection under this new system? * How can you leverage your existing approvals to gain a competitive advantage in LATAM? * What are the key responsibilities of a local representative in this new process? Don't let regulatory shifts derail your market entry. At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI tools to streamline your access to markets like Mexico. Contact us at [email protected] or visit https://pureglobal.com/ for a strategic consultation.

This week, we dive into a major regulatory shift in Latin America's largest MedTech market. Brazil's agency, ANVISA, has just released new, stringent guidance for AI-powered Software as a Medical Device (SaMD). This development creates significant new barriers for foreign manufacturers, moving beyond simple acceptance of international certifications and demanding a highly localized compliance strategy. We explore the three core pillars of this new update: the requirement for clinical data representative of the Brazilian population, specific cybersecurity mandates for data privacy, and the complex new rules for managing self-learning AI algorithms post-market. This episode is essential for any MedTech innovator targeting Brazil. Case Study Spotlight: A French MedTech scale-up, celebrated for its AI diagnostic software with a CE mark, was planning an aggressive Brazilian launch this quarter. Their strategy relied on leveraging their European clinical data. The new ANVISA guidance has abruptly halted their plans, as their data is now deemed insufficient, forcing a costly and time-consuming local validation study they were unprepared for. Key Takeaways: - Does your AI's training data meet ANVISA's new demographic requirements for Brazil? - Is your global cybersecurity plan adequate for Brazil's new, specific reporting protocols? - How will you manage and document post-market changes for your 'learning' algorithm? - Is your existing technical dossier now obsolete under these new SaMD guidelines? - What constitutes a "significant change" for an AI algorithm that requires re-submission to ANVISA? - How can you build a compliant Algorithm Change Protocol from scratch? Navigating the complexities of Brazil's evolving regulatory landscape requires deep local expertise and a proactive strategy. At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies. Our team of local experts, combined with advanced AI tools, helps you develop efficient pathways for regulatory approval, compile technical dossiers, and act as your official in-country representative. We turn regulatory hurdles into market opportunities. Contact us at [email protected] or visit https://pureglobal.com/ to secure your market access.

This week, we dive into a major regulatory shift in Brazil that is catching international MedTech companies off guard. ANVISA's RDC 751/2022 is entering a critical new phase, and the latest clarifications on technical dossier requirements are creating significant hurdles for manufacturers seeking market access. We break down what these changes mean and why your existing FDA or CE mark documentation may no longer be enough. We explore the challenges through a common scenario. Imagine a successful European MedTech company, confident in their CE-marked diagnostic tool, targeting Brazil for their next big expansion. They suddenly face a submission rejection from ANVISA due to "insufficient clinical data" under the new RDC 751 rules. Their launch is now stalled, competitors are gaining ground, and they face the costly, time-consuming task of generating new evidence for a market they don't fully understand. Key Takeaways: * What is the crucial difference between an EU technical file and a Brazilian dossier under RDC 751? * Why is ANVISA's new classification system causing unexpected delays for device makers? * Is your clinical data robust enough for Brazil's heightened scrutiny? * What is the number one documentation mistake companies make when submitting to ANVISA? * How can you turn Brazil's tough regulatory environment into a competitive advantage? * Why might your risk management file be non-compliant, even if it was accepted elsewhere? * What are the unwritten rules for expediting your registration process in Brazil? Navigating the complexities of global markets like Brazil is what we do best. Pure Global offers end-to-end regulatory consulting, combining local expertise with advanced AI tools to streamline market access. Don't let regulatory hurdles derail your expansion. Contact us at [email protected] or visit https://pureglobal.com/ to learn how we can secure your entry into Latin America.

Brazil's national health agency, ANVISA, has just launched a new, comprehensive regulatory framework for Software as a Medical Device (SaMD), with a major focus on AI and digital health technologies. This pivotal update ends years of uncertainty but introduces stricter rules that are reshaping the market entry strategy for all MedTech innovators targeting Latin America's biggest economy. In this episode, we dissect the critical details of this new resolution. We explore the updated risk classification system, the surprising new requirements for local clinical data, and the stringent cybersecurity mandates that now apply. This is a must-listen for any manufacturer or investor who wants to understand the new cost, timeline, and strategic implications of launching a digital health product in Brazil. **Case Study Spotlight:** Imagine your AI-powered diagnostic tool, previously on a straightforward path to market as a Class II device, is suddenly reclassified as high-risk Class III by the new ANVISA rules. This shift instantly triggers the need for expensive, time-consuming local clinical trials, potentially delaying your launch by more than a year. We unpack how to navigate this exact scenario and what it means for your budget and global strategy. **Key Takeaways:** * What are the three most critical changes in ANVISA's new SaMD framework? * How do the new cybersecurity requirements differ from FDA or CE standards? * Is my existing telehealth platform now considered a regulated medical device in Brazil? * What is the single biggest mistake foreign companies make when submitting AI-based digital health dossiers to ANVISA now? * How does this regulatory shift in Brazil impact future trends in Colombia and Mexico? * Are there any new fast-track approval pathways for certain types of SaMD under this resolution? * What kind of local partnerships have become essential for ensuring compliance with these new rules? At Pure Global, we specialize in demystifying complex regulatory landscapes like this. Our integrated approach combines local, in-country experts with advanced AI and data tools to deliver end-to-end solutions—from initial market strategy and technical dossier submission to post-market surveillance. We act as your local representative, ensuring you not only enter the market but thrive in it. To streamline your entry into Brazil or over 30 other markets, contact us at [email protected] or visit https://pureglobal.com/.

In this episode, we dissect the groundbreaking new regulation from Brazil's ANVISA for Software as a Medical Device (SaMD). The country has officially aligned its framework with the global IMDRF standards, a move that promises to streamline market access for international manufacturers. But this harmonization comes with a uniquely Brazilian twist. We explore the hidden complexities beneath the surface. While alignment with international standards simplifies dossier preparation, ANVISA has embedded stringent local requirements for cybersecurity and data privacy, directly linked to Brazil's powerful General Data Protection Law (LGPD). This creates a new hybrid regulatory landscape where a simple copy-paste of your global submission is a recipe for rejection. A real-world case illustrates the challenge. A MedTech company with an FDA-cleared AI diagnostic tool gets its Brazilian application rejected. Their critical mistake was assuming their HIPAA-compliant cybersecurity protocols would satisfy the LGPD-specific requirements now hardwired into ANVISA's SaMD rules, leading to costly delays and rework. Key Takeaways for This Episode: - Is Brazil's new SaMD regulation an open door or a hidden trap for global innovators? - How does the new IMDRF alignment truly impact your existing technical dossier? - What are the most common cybersecurity and data privacy mistakes companies make when entering Brazil? - How could your SaMD's risk classification change under ANVISA's new framework versus the FDA or EU? - Beyond the device itself, what new software validation and lifecycle management proofs are now required? - How can you leverage Brazil's strict LGPD data law as a competitive advantage? - What are the hidden costs of non-compliance with these new localized requirements? Navigating this new environment requires deep local expertise combined with a global perspective. At Pure Global, we offer end-to-end regulatory consulting for MedTech and IVD companies, using our local experts in Brazil and advanced AI tools to streamline market access. We turn regulatory complexity into your competitive advantage. To learn more about our services, contact us at [email protected] or visit us at https://pureglobal.com/.

This week on LATAM MedTech Insights, we dissect the breaking news from Brazil. ANVISA has just launched a new "Agile Approval Program" promising rapid, sub-90-day registration for AI-powered medical software. This move is designed to attract top-tier global technology and accelerate innovation within Latin America's largest market. While the fast-track approval sounds like a golden ticket, it comes with a significant catch. The new regulation includes a strict data privacy addendum linked to Brazil's LGPD law. This creates a critical new set of challenges for foreign manufacturers, focusing on algorithmic bias and data sovereignty. We explore how this seemingly minor detail could derail market entry plans and add unexpected costs and delays. A prime example is a European AI diagnostics firm, poised for rapid entry into Brazil's market. They are now facing unexpected delays and significant costs due to unforeseen local data hosting and algorithmic bias validation requirements. Their initial strategy, built on leveraging their existing FDA clearance, is now obsolete, forcing a costly scramble to meet local data compliance. Key Takeaways: - What is Brazil's new fast-track pathway for AI-powered medical devices? - How could ANVISA's new data privacy rules unexpectedly block your market entry? - Why is proving your AI is free from demographic bias now a regulatory requirement in Brazil? - Are you prepared for mandatory local data handling protocols and their hidden costs? - How can a regulation designed to speed up approvals actually slow you down? - What steps can you take to turn Brazil's complex LGPD rules into a competitive advantage? - Is your existing technical dossier sufficient for this new, data-centric review process? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as your local representative, develop efficient regulatory strategies, and use advanced AI to compile and submit technical documents, ensuring you can navigate complex challenges like Brazil's new AI regulations. To prepare your market access strategy, contact us at [email protected] or visit https://pureglobal.com/.

This episode of LATAM MedTech Insights dives into the critical challenges emerging from Brazil's new medical device regulation, RDC 751/2022. As of last week, an increasing number of international manufacturers are facing surprising rejections from ANVISA. The issue goes far beyond simple paperwork; it reflects a fundamental misunderstanding of the heightened scrutiny now applied to clinical data, risk management, and technical documentation. We explore the hidden complexities that are tripping up even experienced regulatory affairs teams. We break down the specific areas where ANVISA is focusing its attention, from demanding localized clinical evidence to flagging minor inconsistencies in product labeling. This episode is essential for any MedTech company looking to enter or maintain its presence in the Brazilian market. **What You'll Learn:** - Why is Brazil's RDC 751 proving to be more than just a document reformatting exercise? - What is the single biggest mistake foreign manufacturers are making in their new ANVISA submissions? - How can your existing CE-marked or FDA-approved clinical data lead to a rejection in Brazil? - Are you correctly understanding the difference between device 'grouping' (agrupamento) and 'kits' (conjunto)? - What are the unwritten expectations from ANVISA reviewers when they examine your technical dossier? - How can you avoid a six-month delay by getting your Instructions for Use and labeling right the first time? - How can you transform the challenges of RDC 751 into a strategic advantage for market entry? Navigating global markets requires deep local expertise and cutting-edge tools. Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, leveraging local experts in Brazil and advanced AI to streamline market access. From initial regulatory strategy to post-market surveillance, we act as your local representative to ensure your success. To learn how we can help you conquer the Brazilian market, contact us at [email protected] or visit https://pureglobal.com/.

This week on LATAM MedTech Insights, we dissect the ongoing regulatory shake-up in Brazil. ANVISA's RDC 751/2022 is now in full force, and medical device manufacturers are facing a complex new reality. We unpack the critical changes, moving beyond the headlines to explore the on-the-ground impact of the new technical dossier structure and reclassification rules. We explore the long-term vision behind this push for harmonization with global standards and contrast it with the immediate, resource-intensive hurdles companies must overcome. This episode is essential listening for any MedTech professional with stakes in the Brazilian market. For example, consider a successful US-based IVD manufacturer whose product has been on the Brazilian market for years. Under RDC 751, their device is now in a higher risk class and their existing technical file is obsolete. How can they possibly compile, translate, and submit a completely new dossier that meets the stringent new structure before their current license expires and their multi-million dollar revenue stream is cut off? What You'll Learn: - What are the three most common deficiencies ANVISA is finding in new RDC 751 submissions? - How does the new technical file structure differ from the US FDA 510(k) or EU MDR requirements? - Is your current Brazil Registration Holder (BRH) equipped to handle these complex new requirements? - What's the biggest mistake companies make when updating their risk management files for ANVISA? - Could this regulatory challenge actually be a strategic opportunity to leapfrog competitors? - How will Brazil's alignment with the IMDRF framework impact your expansion plans in other LATAM countries? At Pure Global, we specialize in transforming regulatory complexity into market opportunity. Our team of local experts in Brazil, combined with our AI-powered data tools, provides end-to-end solutions for MedTech and IVD companies. Whether it's conducting a gap analysis for RDC 751, managing technical dossier submissions, or acting as your official local representative, we streamline your path to market. Don't let regulatory changes disrupt your business. Contact us for a consultation at [email protected] or visit https://pureglobal.com/ to learn more.

Brazil's health agency, ANVISA, just dropped its regulatory agenda for 2026-2027, and it’s set to reshape the landscape for medical device manufacturers. This new roadmap signals a major pivot from one-time market approval to a continuous, full-lifecycle approach to regulation, with big implications for SaMD, clinical data, and post-market surveillance. For any MedTech company with a high-risk device, the pain point is immediate. Your existing FDA or CE Mark clinical data might no longer be enough to secure or maintain your registration in Brazil. You're now facing the challenge of generating local Real-World Evidence, a potentially costly and complex process. But the attraction is clear: successfully navigating these new requirements unlocks continued access to one of the world's most lucrative and rapidly growing healthcare markets. Key Takeaways: - How will ANVISA's new agenda impact your 2026 product registration timeline? - Is your Software as a Medical Device prepared for Brazil's new cybersecurity standards? - What now constitutes acceptable Real-World Evidence for the Brazilian population? - Could a new fast-track process for low-risk devices actually increase your compliance burden? - How does ANVISA's focus on lifecycle management affect your post-market responsibilities? - Are your global clinical studies designed to meet Brazil's new data expectations? - What changes do you need to make to your quality management system right now? At Pure Global, we specialize in turning these regulatory shifts into strategic advantages. With our local expertise in Brazil and advanced AI tools, we develop efficient pathways for regulatory approval, manage technical dossier submissions, and act as your local representative to ensure you not only enter the market but thrive in it. Don't let regulatory changes disrupt your plans. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

A major regulatory shift just hit Brazil, Latin America's top MedTech market. Last week, the national agency ANVISA rolled out a completely new framework for Software as a Medical Device (SaMD), creating urgent challenges and new opportunities for digital health companies worldwide. This update introduces a stricter, four-tiered risk classification system and demands more rigorous technical documentation, especially for AI- and machine learning-driven software. This change means the old way of registering your SaMD product in Brazil is no longer valid. Consider a European startup with an innovative AI diagnostic tool that analyzes patient data to predict disease progression. Under the previous, more ambiguous rules, they were preparing for a mid-tier regulatory process. Now, their product is definitively classified as high-risk, requiring extensive new evidence on clinical validation, data privacy, and cybersecurity that they hadn't budgeted for, potentially delaying their market entry by months. Key questions from this episode: - How does ANVISA's new risk classification system impact your AI-powered diagnostic tool? - What specific cybersecurity and data privacy documents are now mandatory for your submission? - How has the definition of a medical device been expanded to include your wellness or diagnostic app? - What are the new, stringent requirements for clinical validation for high-risk SaMD? - How can you perform a gap analysis between your existing technical file and the new Brazilian requirements? - Will your existing ISO 13485 certification be enough to meet the new quality management system expectations for software? - How will these changes affect registration timelines and costs for entering the Brazilian market? At Pure Global, we specialize in navigating these complex regulatory landscapes. We provide end-to-end regulatory consulting for MedTech and IVD companies, using local expertise and advanced AI tools to streamline your market access. Whether you're a startup or a multinational, we can help you adapt your strategy, update your technical dossiers, and ensure a successful launch in Brazil and over 30 other markets. Contact us at [email protected] or visit https://pureglobal.com/.

In this episode, we dissect a major regulatory shift in Mexico. A new reform to the General Health Law has extended medical device registration renewals to a 10-year cycle, a significant jump from the previous five years. This change presents a massive opportunity for manufacturers, offering long-term market stability and reduced administrative burdens. While this extension is a welcome development, it also introduces a new paradigm of compliance. With a decade-long gap between renewals, the focus intensifies on continuous post-market surveillance and vigilance. We explore the strategic pivot required for companies to thrive in this new environment, moving from a short-term renewal sprint to a long-term compliance marathon. A Case to Consider: Imagine your company has just secured a 10-year registration for its flagship diagnostic device in Mexico. The immediate cost savings are clear. But the real challenge is ensuring your vigilance and quality systems are robust enough to stand up to a decade of scrutiny from COFEPRIS without the regular check-in of a 5-year renewal. How do you maintain perfect compliance over such a long period? Key Takeaways: - What specific article of Mexico's General Health Law has changed for medical devices? - How does a 10-year registration cycle fundamentally alter a manufacturer's financial planning? - Why might this change make Mexico a more attractive long-term investment than other LATAM markets? - What are the hidden compliance risks of having a longer period between renewal submissions? - How must companies adapt their post-market surveillance strategies for this new "marathon"? - Could this strategic move by COFEPRIS influence regulators like ANVISA or INVIMA? - What kind of local operational support becomes critical for maintaining a 10-year registration? At Pure Global, we specialize in navigating these complex regulatory landscapes. Our end-to-end solutions, combining local expertise with advanced AI tools, streamline global market access. We handle everything from initial strategy to post-market surveillance, ensuring your innovation reaches the market and stays there. Don't let regulatory hurdles slow you down. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.

This week, we dive into a critical regulatory shift in Latin America's largest MedTech market. Brazil's ANVISA has just issued new, stringent guidelines for Software as a Medical Device (SaMD), specifically targeting the booming field of AI-powered diagnostics. This update reshapes the pathway to market for innovators both inside and outside Brazil. We break down exactly what has changed, focusing on the new risk classifications and the intensified requirements for local clinical data. This episode is essential for any MedTech manufacturer, investor, or regulatory professional looking to understand the evolving landscape in Brazil and what it takes to succeed there now. **Case Study Spotlight:** Imagine your company has an innovative AI tool for detecting diabetic retinopathy, ready for Brazilian launch with a Class II strategy. Suddenly, new ANVISA guidance reclassifies your product to high-risk Class III, demanding extensive local clinical trials and delaying your launch by over a year. We discuss the strategic pivot required to overcome this exact challenge. **In this episode, you will learn:** - What are the key differences in ANVISA's new SaMD classification system for AI? - How do the new Brazilian guidelines align with international standards like the EU MDR? - What specific clinical evidence is now required for a high-risk SaMD submission in Brazil? - Does this new framework create more barriers or opportunities for foreign developers? - What are the most common pitfalls to avoid when submitting your AI SaMD for approval under the new rules? - How can you leverage existing global data while satisfying the new local requirements? - What does this mean for the future of digital health investment in Latin America? Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies. We combine local expertise with advanced AI to streamline market access in complex, evolving markets like Brazil. Facing challenges with the new SaMD regulations? Contact Pure Global at [email protected] or visit us at https://pureglobal.com/ for a strategic consultation.

In this episode, we dissect the breaking news from Mexico's health authority, COFEPRIS. A new reform extends medical device registration renewals from five years to a full decade. This change is poised to reshape market strategy for all MedTech companies in the region. While this extension appears to be a major win by reducing administrative burdens, it introduces subtle but significant long-term risks. We explore the hidden compliance traps, the increased importance of post-market surveillance, and why this regulatory gift could become a major liability for businesses that fail to adapt their operational mindset from cyclical renewals to continuous vigilance. A real-world example of the risk is a company that secures a 10-year registration for its Class II device. In year four, COFEPRIS issues a new guidance on cybersecurity reporting for software-enabled devices. The company, focused on other market entries and no longer preparing for a renewal, misses the update. In year seven, a minor audit reveals this non-compliance, leading to fines and a potential suspension of their registration, jeopardizing a decade of projected revenue. Key questions from this episode: - Why does a 10-year approval cycle demand more vigilance, not less? - How will COFEPRIS likely shift its enforcement focus now? - What is the biggest mistake a company can make after securing a 10-year registration in Mexico? - How does this regulatory change impact your long-term budget planning? - Is your current post-market surveillance system robust enough for this new paradigm? - What tools can ensure your technical file remains a 'living document' for a full decade? - How can you turn this regulatory change into a competitive advantage? Navigating the complexities of long-term market access requires local expertise and global strategic oversight. Pure Global offers end-to-end regulatory consulting for MedTech companies, using advanced AI and data tools to streamline global market access and ensure continuous compliance. Let us help you build a robust, decade-long regulatory strategy. Contact us at [email protected] or visit https://pureglobal.com/.

Brazil's health agency, ANVISA, has just unveiled its ambitious 2026-2027 regulatory agenda, signaling one of the most significant shifts in the Latin American MedTech landscape in years. This isn't just a minor update; it's a fundamental move towards stricter, globally harmonized standards that will redefine market access. This episode of LATAM MedTech Insights dives deep into the two most critical changes: a complete overhaul of the rules for Software as a Medical Device (SaMD) and the game-changing proposal to make MDSAP audits mandatory for all manufacturers. We break down the immediate operational and strategic impact these changes will have on your business. A US-based digital health startup just received FDA clearance for its AI-powered diagnostic tool. They saw Brazil as their next big market, but the planned revision of RDC 657 means their existing validation data might be insufficient for ANVISA. They now face a potential rework of their entire technical file, delaying market entry by over a year and adding unexpected six-figure costs. We discuss how to avoid this trap. This Episode's Key Questions: - How will ANVISA's new SaMD regulation impact AI and machine learning devices? - Is mandatory MDSAP participation a certainty for Brazil, and what is the deadline to prepare? - What are the three key documents you need to update in your technical file for the new software rules? - How can you leverage your existing certifications to streamline the new Brazilian requirements? - What is the number one mistake foreign manufacturers make when interpreting ANVISA's agenda? - Will the validity of Good Manufacturing Practices certificates finally be extended to align with product registrations? At Pure Global, we specialize in turning these regulatory challenges into market opportunities. With our local experts in Brazil and advanced AI tools, we streamline the entire market access process, from regulatory strategy and technical dossier preparation to acting as your official in-country representative. Don't let regulatory hurdles block your entry into one of the world's largest MedTech markets. Contact us at [email protected] or visit https://pureglobal.com to secure your market presence.

In this episode, we dive into a major regulatory shift that just happened in Mexico. Last week, COFEPRIS officially extended the renewal period for medical device registrations from five to ten years. This change presents a massive opportunity for MedTech manufacturers, reducing long-term costs and administrative burdens. We explore the practical implications of this reform, discussing how it repositions Mexico as a more attractive market within the LATAM region. We also uncover the potential challenges and new expectations this places on companies, particularly regarding long-term post-market surveillance and compliance. This isn't just a simple extension; it's a strategic move that requires a new way of thinking about your market presence in Mexico. **Key Takeaways:** * What specific change in Mexico's General Health Law doubles the life of a device registration? * How does the new 10-year renewal period impact the long-term cost and strategy for my products in Mexico? * Are all classes of medical devices eligible for this new extension? * With a longer registration, what are COFEPRIS's new expectations for post-market surveillance? * Should this regulatory shift in Mexico cause me to reconsider my expansion plans in other LATAM countries like Brazil or Colombia? * What steps should I take now to prepare my existing registrations for this new ten-year cycle? At Pure Global, we offer end-to-end regulatory consulting solutions to help MedTech and IVD companies navigate exactly these kinds of changes. We combine local expertise with advanced AI and data tools to streamline global market access, manage your technical dossiers, and ensure continuous compliance. Let us help you turn regulatory changes into strategic advantages. Contact us at [email protected] or visit https://pureglobal.com/.